Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544052 | 1.00 | TEAD1 (0.40) | TEAD1YAP1TP53MAPTJAK2 | |
| SCHEMBL25338341 | 0.80 | TAS2R14 (0.40) | TEAD1YAP1TP53MAPTAKR1C3 | |
| SCHEMBL25952101 | 0.80 | BRD4 (0.39) | TP53JAK2JAK3 | |
| SCHEMBL25339003 | 0.80 | SLC6A2 (0.38) | MAPTMAT2A | |
| SCHEMBL30544058 | 0.80 | SLC6A2 (0.38) | MAPTMAT2A | |
| SCHEMBL30544084 | 0.75 | ALOX5AP (0.44) | TEAD1YAP1TP53MAPTJAK2 | |
| SCHEMBL25429357 | 0.73 | TP53 (0.42) | TEAD1YAP1TP53MAPTJAK2 | |
| SCHEMBL25377073 | 0.72 | TP53 (0.45) | TEAD1YAP1TP53MAPTJAK2 | |
| SCHEMBL30482521 | 0.72 | TP53 (0.45) | TEAD1YAP1TP53MAPTJAK2 | |
| SCHEMBL25955668 | 0.72 | TEAD1 (0.37) | TEAD1YAP1TP53MAPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |